Phase 2 clinical trial data published in 2023 in the New England Journal of Medicine (Jastreboff et al., NEJM 2023) demonstrated substantial weight reduction in participants with obesity
Conlon, J.M., O'Harte, F.P.M., Flatt, P.R
The key insulinotropic actions of GLP-1 via the class B1 G-protein-coupled receptor (GPCR) are exerted by cyclic adenosine monophosphate (cAMP) formation, which, in conjunction with increased Ca 2+ levels, promotes exocytosis of insulin-containing vesicles [39]
Addiction and withdrawal support : Some private clinics offer NAD injections as part of addiction treatment protocols, particularly for alcohol and opioid dependence
Boost Energy, Metabolism, and Focus